Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Asset Writedowns and Impairment: 2021-2023

Historic Asset Writedowns and Impairment for Oncology Institute (TOI) over the last 3 years, with Q4 2023 value amounting to $2.0 million.

  • Oncology Institute's Asset Writedowns and Impairment rose 258783.78% to $2.0 million in Q4 2023 from the same period last year, while for Jun 2024 it was $2.0 million, marking a year-over-year increase of 262465.75%. This contributed to the annual value of $2.0 million for FY2023, which is 32436.97% up from last year.
  • Per Oncology Institute's latest filing, its Asset Writedowns and Impairment stood at $2.0 million for Q4 2023, which was up 258783.78% from $33000.0 recorded in Q3 2023.
  • In the past 5 years, Oncology Institute's Asset Writedowns and Impairment registered a high of $2.0 million during Q4 2023, and its lowest value of -$722000.0 during Q2 2021.
  • In the last 3 years, Oncology Institute's Asset Writedowns and Impairment had a median value of $74000.0 in 2022 and averaged $189000.0.
  • Within the past 5 years, the most significant YoY rise in Oncology Institute's Asset Writedowns and Impairment was 258783.78% (2023), while the steepest drop was 10285.71% (2023).
  • Over the past 3 years, Oncology Institute's Asset Writedowns and Impairment (Quarter) stood at $250000.0 in 2021, then crashed by 70.4% to $74000.0 in 2022, then soared by 2587.84% to $2.0 million in 2023.
  • Its Asset Writedowns and Impairment was $2.0 million in Q4 2023, compared to $33000.0 in Q3 2023 and -$3000.0 in Q2 2023.